Abstract
Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Current Pharmaceutical Design
Title: Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications
Volume: 8 Issue: 3
Author(s): J. L. Burgaud, J. P. Riffaud and P. Del Soldato
Affiliation:
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Abstract: Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Export Options
About this article
Cite this article as:
Burgaud L. J., Riffaud P. J. and Soldato Del P., Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications, Current Pharmaceutical Design 2002; 8 (3) . https://dx.doi.org/10.2174/1381612023396357
DOI https://dx.doi.org/10.2174/1381612023396357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Exercise Preconditioning Reduces Brain Damage and Inhibits TNF-α Receptor Expression after Hypoxia/Reoxygenation: An In Vivo and In Vitro Study
Current Neurovascular Research Editorial: The Need for an Effective Hangover Cure
Current Drug Abuse Reviews Modulation of the Immune System for the Treatment of Glaucoma
Current Neuropharmacology Adherence and Assured Administration of Medications in Bipolar Patients
Current Drug Delivery Animal Models of Maternal Immune Activation in Depression Research
Current Neuropharmacology Voltammetric Method for Simultaneous Determination of L-Dopa and Benserazide
Current Analytical Chemistry Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Analysis of Genetic Variants in SCN1A, SCN2A, KCNK18, TRPA1 and STX1A as a Possible Marker of Migraine
Current Genomics Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Epigenetics, Gender, and Sex in the Diagnosis of Depression
Current Psychiatry Research and Reviews Screening for New Agonists Against Alzheimers Disease
Medicinal Chemistry Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Intestinal MicrobiOMICS to Define Health and Disease in Human and Mice
Current Pharmaceutical Biotechnology Application of Nanomaterials in Neurodegenerative Diseases
Current Stem Cell Research & Therapy Photopolymerizable Resins for 3D-Printing Solid-Cured Tissue Engineered Implants
Current Drug Targets